HIV Infections Clinical Trial
— HNPOfficial title:
Increasing Animal Source Foods in Diets of HIV-Infected Kenyan Women and Their Children
Many of the 28 million people with immunodeficiency virus (HIV) and acquired
immunodeficiency syndrome (AIDS) estimated to be living in sub-Saharan Africa also suffer
from malnutrition. Reproductive age women, their infants and young children are among the
most vulnerable for malnutrition and progression of HIV to AIDS and mortality is increased
in the malnourished, as seen in Eastern and Southern Africa. The HIV Nutrition Project (HNP)
research evaluates the effect of protein and micronutrients in meat on the health and
nutritional well being of Kenyan women living with HIV in rural Kenya and the health and
development of their children, by means of a randomized nutrition intervention. We will
determine if meat in the diets of HIV- infected women and their children (1) protects the
immune system and prevents severe infection, (2) prevents the loss of body mass and enhances
the quality of life among drug naïve women not yet ill enough to warrant antiretroviral
drugs and (3) positively impacts growth and development of vulnerable children of the
HIV-infected women when compared to those given supplements with the same amount of energy
but with either soya or wheat protein. The intervention food with beef protein provides
significant vitamin B12, lysine and bio-available iron, zinc and selenium when compared to
the soya and wheat supplements. Deficiencies of these nutrients may hasten HIV disease
progression.
The findings from our project may have implications for the development of initiatives that
are either sustainable or subsidized by the local, regional and/or global economies that
ensure that all HIV-infected individuals have access to adequate nutrition support that
includes foods that provide enough nutrients that are needed to optimize health and
well-being. The knowledge gained may significantly impact other populations at high risk for
decreased immune function such as those with tuberculosis and malaria.
This is a 3 arm randomized design where 225 HIV-infected rural Kenyan mothers with a CD4
between 250 and 500, WHO Stage 1 or 2, and with no co-existing infections, receive with
their child, a nutrition biscuit supplement daily (5 days/week) for 12 months. These women
are not yet ill enough to warrant treatment with antiretroviral drugs in Kenya and therefore
a food intervention may keep them healthy longer and delay the need for drugs.
| Status | Completed |
| Enrollment | 808 |
| Est. completion date | June 2012 |
| Est. primary completion date | June 2012 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 6 Months and older |
| Eligibility |
HIV-infected women and their children who live in the Turbo catchment area in the Uasin
Gishu District of Kenya and attend the AMPATH clinic there will be invited to participate
in the study. Inclusion Criteria: - Women will be included if drug naïve and classified as WHO Stage 1 or 2 54 with a CD4 count greater than 250. - The youngest child in the household between 6 months and 10 years who has no evidence of one or more OIs or illnesses will also be followed. Exclusion Criteria: - Women will be excluded if the initial CD4 is less than or equal to 250, they suffer from one or more OIs, are pregnant, or qualify as recipients of the AMPATH standard of care HHI, World Food Program or USAID Unimix food supplement interventions. - Should the designated child be HIV positive with advanced disease and therefore not meet inclusion criteria, the next oldest child less than 10 years who meets the study criteria will be the designated child. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Kenya | Moi University-Academic Model for the Prevention and Treatment of HIV | Eldoret | Rift Valley Province |
| Lead Sponsor | Collaborator |
|---|---|
| Indiana University School of Health & Rehabilitation Sciences | Heifer Project International, Moi Univeristy, United States Agency for International Development (USAID), University of California, Los Angeles, USDA, Western Human Nutrition Research Center |
Kenya,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The impact of meat intake on mid-upper-arm muscle area; comparisons between groups, of changes from baseline to 3, 6, 9, 12, 15, 18 mos (intervention); 24 mos (6 mos post intervention). | 24 months | No | |
| Secondary | The impact of meat intake on immune function (CD4 as well as percent of CD4 in the total lymphocyte); change from baseline to 6, 12, 18 mos (intervention), 24 months (6 mos post intervention)will be compared between groups | 24 months | No | |
| Secondary | The impact of meat intake on opportunistic infection (OI) incidence will be assessed monthly; change over time will be compared between groups from baseline through 18 mos (intervention and at 24 mos (6 mos post intervention). | 24 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |